Clin2
NCT06903377Possibly a fitRecruiting

ZG005 plus Gecacitinib for advanced lung cancer

Non-small Cell Lung Cancer

Treatments studied

Part of Cancer, Lungs & breathing clinical trials.

This trial tests a new combination of two drugs, ZG005 and Gecacitinib, for people with advanced non-small cell lung cancer that cannot be treated with surgery or radiation. The goal is to see if the combination can shrink or slow the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
50 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must be between 18 and 75 years old.
  • You must have advanced or spread non-small cell lung cancer that has been confirmed by a biopsy.
  • Your cancer must not be able to be treated with surgery or radiation to cure it.
  • You cannot have had cancer in another part of your body in the last 5 years (except for some early skin cancers).
  • You cannot have cancer that has spread to your brain (central nervous system metastases) unless it has been treated and is stable.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06295432Recruiting· Phase 2
Study of two targeted drugs for EGFR-mutated lung cancer

This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.

Guangzhou, Guangdong
NCT06883526Recruiting· Phase 1/Phase 2
ZG005 plus gecacitinib for lymphoma that has returned or not responded

This trial tests a combination of two drugs, ZG005 and gecacitinib, for people with lymphoma that has come back or hasn't gotten better with prior treatment. The goal is to see if this combination can help shrink or control the cancer.

Hangzhou, Zhejiang
NCT07080216Recruiting· Phase 1/Phase 2
Study of ZG005 and Gecacitinib for advanced cervical cancer

This trial tests a combination of two new drugs, ZG005 and Gecacitinib, for people with advanced cervical cancer that has spread or come back. The goal is to see if the combination can shrink tumors or slow the cancer's growth.

Hangzhou, Zhejiang
NCT06283719Recruiting· Phase 1/Phase 2
ZG006 for advanced small cell lung cancer or neuroendocrine tumors

This trial tests a new drug called ZG006 for people with advanced small cell lung cancer or a type of neuroendocrine cancer. It aims to find the best dose and see if it helps shrink tumors.

Shanghai, Shanghai Municipality
NCT06233292Recruiting· Phase 1/Phase 2
Study of ZG005 for advanced solid tumors

This trial tests a new drug called ZG005 in people with advanced solid tumors that have not spread to the brain. It aims to see if the drug is safe and can help shrink tumors.

Hangzhou, Zhejiang
NCT07231445Recruiting· Phase 1
ZG006 with immunotherapy for extensive small cell lung cancer

This trial tests a new drug, ZG006, combined with standard immunotherapy (PD-1/PD-L1 inhibitors) for people with advanced small cell lung cancer that hasn't been treated before. The goal is to find out if this combination works better than the current standard care.

Shanghai, Shanghai Municipality

Hear when a new Non Small Cell Lung Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.